Entity

Time filter

Source Type

North Ryde, Australia

Patent
Clinical Genomics Pty Ltd | Date: 2013-11-26

The present invention relates to a method of screening for the presence of methylated DNA in a biological sample by using multiple methylation-sensitive restriction endonucleases. More particularly, the present invention relates to a method of quantitatively screening for the level of one or more methylated genes of interest without the requirement that an undigested internal reference sample is used as a point of reference against which relative quantification is calculated. The present invention is useful in a range of applications including, but not limited to, providing a simpler and more accurate means to determine DNA methylation status, such as in the context of diagnosing or monitoring conditions characterised by changes to DNA methylation.


Patent
Clinical Genomics Pty. Ltd. | Date: 2010-04-22

A method for isolating a target bioentity from a biological sample, comprises contacting the biological sample with a magnetically-labelled ligand having selective binding affinity for the target bioentity, or for a determinant on the target bioentity, to form a target bioentity/labelled ligand complex, locating a separation module having a defined fluid flow path in the magnetic field of a magnetic module, the magnetic module comprising an array of at least two magnets in which adjacent magnets in the array are aligned with opposing polarity; passing the biological sample through the separation module to subject the biological sample to the magnetic field while the sample is passing through the defined fluid flow path to magnetically capture the target bioentity/labelled ligand complex by arresting or hindering movement of the complex within the defined fluid flow path; removing the separation module from the magnetic field; and recovering the target bioentity/labelled ligand complex from the fluid flow path.


Patent
Csiro and Clinical Genomics Pty. Ltd. | Date: 2013-10-18

The present invention relates generally to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the DNA or to the RNA or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The DNA or the expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the DNA or the RNA or protein expression profile of one or more nucleic acid molecule markers.


Patent
Clinical Genomics Pty. Ltd. | Date: 2011-10-26

The present invention relates to a method of enriching for membranous microvesicles relative to the cellular population in a biological sample. More particularly, there is provided a method for enriching for exosomes from plasma. In a related aspect, there is provided a method of reducing the concentration of cellular and cellular derived molecules in a biological sample. Still further, the present invention provides methods for selectively isolating mRNA subpopulations from exosomes. Yet further, there are provided methods of amplifying exosome derived RNA. The method of the present invention is useful in a range of applications including, but not limited to, diagnostic, prognostic, therapeutic, research and development applications, to the extent that the enrichment of exosomes is required.


Patent
Csiro and Clinical Genomics Pty. Ltd. | Date: 2011-09-13

The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.

Discover hidden collaborations